Vis enkel innførsel

dc.contributor.authorBrønstad, Ingeborgen_US
dc.contributor.authorBreivik, Lars Ertesvågen_US
dc.contributor.authorMethlie, Paalen_US
dc.contributor.authorWolff, Anette Susanne Bøeen_US
dc.contributor.authorBratland, Eiriken_US
dc.contributor.authorNermoen, Ingriden_US
dc.contributor.authorLøvås, Kristianen_US
dc.contributor.authorHusebye, Eystein Sverreen_US
dc.date.accessioned2015-04-14T13:17:03Z
dc.date.available2015-04-14T13:17:03Z
dc.date.issued2014eng
dc.identifier.issn2049-3614
dc.identifier.urihttps://hdl.handle.net/1956/9782
dc.description.abstractIn about 95% of cases, congenital adrenal hyperplasia (CAH) is caused by mutations in CYP21A2 gene encoding steroid 21-hydroxylase (21OH). Recently, we have reported four novel CYP21A2 variants in the Norwegian population of patients with CAH, of which p.L388R and p.E140K were associated with salt wasting (SW), p.P45L with simple virilising (SV) and p.V211MCp.V281L with SV to non-classical (NC) phenotypes. We aimed to characterise the novel variants functionally utilising a newly designed in vitro assay of 21OH enzyme activity and structural simulations and compare the results with clinical phenotypes. CYP21A2 mutations and variants were expressed in vitro. Enzyme activity was assayed by assessing the conversion of 17-hydroxyprogesterone to 11-deoxycortisol by liquid chromatography tandem mass spectroscopy. PyMOL 1.3 was used for structural simulations, and PolyPhen2 and PROVEAN for predicting the severity of the mutants. The CYP21A2 mutants, p.L388R and p.E140K, exhibited 1.1 and 11.3% of wt 21OH enzyme activity, respectively, in vitro. We could not detect any functional deficiency of the p.P45L variant in vitro; although prediction tools suggest p.P45L to be pathogenic. p.V211M displayed enzyme activity equivalent to the wt in vitro, which was supported by in silico analyses. We found good correlations between phenotype and the in vitro enzyme activities of the SW mutants, but not for the SV p.P45L variant. p.V211M might have a synergistic effect together with p.V281L, explaining a phenotype between SV and NC CAH.en_US
dc.language.isoengeng
dc.publisherBioscientificaeng
dc.rightsAttribution CC BYeng
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/deed.en_GBeng
dc.subjectCYP21A2eng
dc.subjectcongenital adrenal hyperplasiaeng
dc.subjectfunctional studieseng
dc.subjectnovel mutationseng
dc.titleFunctional studies of novel CYP21A2 mutations detected in Norwegian patients with congenital adrenal hyperplasiaen_US
dc.typePeer reviewed
dc.typeJournal article
dc.date.updated2015-04-01T09:24:58Zen_US
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright 2014 The Authors
dc.identifier.doihttps://doi.org/10.1530/ec-14-0032
dc.identifier.cristin1182055
dc.source.journalEndocrine Connections
dc.source.4015
dc.source.143
dc.source.pagenumber67-74
dc.subject.nsiVDP::Medical sciences: 700::Clinical medical sciences: 750::Endocrinology: 774eng
dc.subject.nsiVDP::Medisinske fag: 700::Klinisk medisinske fag: 750::Endokrinologi: 774nob


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Attribution CC BY
Med mindre annet er angitt, så er denne innførselen lisensiert som Attribution CC BY